Trial Profile

A clinical study evaluating the safety, tolerability, and immunogenicity of an Omicron-based vaccine in healthy adults greater than 55 years of age

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omicron-specific COVID-19 vaccine-BioNTech/Pfizer (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Registrational

09 May 2022 According to a BioNTech media release, this study also includes cohorts evaluating a bivalent Omicron-adapted vaccine. Data update from this study is now expected in the coming weeks and will be shared with regulatory agencies.
06 Apr 2022 New trial record
30 Mar 2022 According to a BioNTech media release, the company expects to publish data from this trial in April 2022 supporting potential regulatory submissions for an Omicron-adapted vaccine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com